ARHGAP42

Across TCGA pan-cancer cohorts, ARHGAP42 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP42 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARHGAP42 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP42 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where ARHGAP42 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.439	0.771	.001	39	view →
CCRCC	DFS	Median	III,IV	0.712	0.447	.021	18	view →
UCEC	DFS	Quartile	All	0.931	0.711	.008	12	view →
LSCC	DFS	Median	II,III,IV	0.546	0.799	.026	3	view →
PDAC	OS	Quartile	II,III,IV	0.363	0.639	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGAP42–LUAD (DFS)

Open the LUAD breakdown →